GMED vs IRMD

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 21, 2026

GMED

46.3
AI Score
VS
IRMD Wins

IRMD

50.5
AI Score

Investment Advisor Scores

GMED

46score
Recommendation
HOLD

IRMD

51score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric GMED IRMD Winner
Revenue 1.55B 42.44M GMED
Net Income 275.87M 11.04M GMED
Net Margin 17.8% 26.0% IRMD
Operating Income 332.82M 13.63M GMED
ROE 5.8% 10.8% IRMD
ROA 5.0% 9.6% IRMD
Total Assets 5.49B 114.97M GMED
Cash 507.75M 59.08M GMED
Current Ratio 4.62 9.46 IRMD
Free Cash Flow 339.32M 13.64M GMED

Relative Price Performance (Last 90 Days)

GMED 1M: +4.6% · 3M: +4.3% IRMD 1M: +1.5% · 3M: -6.4%

Current Technical Phase

GMED

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 57

RSI (14): 57.1 · Price: $78.68

IRMD

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 54

RSI (14): 53.9 · Price: $87.81

Fundamentals Snapshot

Metric GMED IRMD
Market Cap — —
Forward P/E 14.6 35.8
Trailing P/E 20.2 49.3
Revenue (TTM) — —
Revenue Growth 0.1% 0.0%
Gross Margin 0.7% 0.8%
Operating Margin 0.2% 0.3%
EPS 3.90 1.79
Dividend Yield — 0.01%

Frequently Asked Questions

Based on our detailed analysis, IRMD is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.